Recently, the State Drug Administration approved the launch of Moxil capsules in the Class 1 innovative drug declared by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., suitable for adult patients with locally advanced or metastatic breast cancer with positive hormone receptors and negative human epidermal growth factor receptor 2 who have progressed after receiving endocrine treatment in combination with fluvizil. The launch of this drug provides patients with new treatment options.

Zhitongcaijing · 3d ago
Recently, the State Drug Administration approved the launch of Moxil capsules in the Class 1 innovative drug declared by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., suitable for adult patients with locally advanced or metastatic breast cancer with positive hormone receptors and negative human epidermal growth factor receptor 2 who have progressed after receiving endocrine treatment in combination with fluvizil. The launch of this drug provides patients with new treatment options.